In short
NOVAVAX, INC. (NVAX) has revenue up 64.7% to $1.1B year on year. Its net margin is 39.2%. Fisclear flags 2 high-severity risks, led by: Negative operating cash flow of $244.6M — the core business consumed more cash than it generated. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$7.47
$1.2B
52-Week Range
Decision Context
Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.1%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — NVAX
Inflationary BoomStrengths
Net Income: $440.3M (+334.8% YoY) — Profit grew 335% — the company kept more of each dollar earned.
EPS (Diluted): $2.58 (+309.8% YoY) — Earnings per share rose 310% — each share earned more.
Revenue: $1.1B (+64.7% YoY) — Revenue grew 65% — the company sold more goods or services than the prior year.
Weaknesses
Operating Cash Flow: -$244.6M (-180.3% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Total Assets: $1.2B (-24.6% YoY) — Total assets shrank 25% — the balance sheet contracted.
R&D spending is 30% of revenue — heavy investment in future growth, but also a drag on current profitability.
Beta of 2.72x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Opportunities
No clear opportunities identified at this time.
Threats
Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.
Total liabilities are 111% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Year-over-Year Changes
Net Income
$440.3M
was -$187.5M
Profit grew 335% — the company kept more of each dollar earned.
EPS (Diluted)
$2.58
was $-1.23
Earnings per share rose 310% — each share earned more.
Operating Cash Flow
-$244.6M
was -$87.3M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Revenue
$1.1B
was $682.2M
Revenue grew 65% — the company sold more goods or services than the prior year.
Total Assets
$1.2B
was $1.6B
Total assets shrank 25% — the balance sheet contracted.
Risk Flags
2 high · 0 medium · 2 low- ⚠ High
Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.
- ⚠ High
Total liabilities are 111% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
- ○ Low
R&D spending is 30% of revenue — heavy investment in future growth, but also a drag on current profitability.
- ○ Low
Beta of 2.72x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Technical Signals
Daily closes · 1-year dataNOVAVAX, INC.: common questions
Is NOVAVAX, INC. profitable?
Yes. NOVAVAX, INC. made a net profit of $440M in its latest fiscal year (fiscal 2025), a net margin of 39.2%.
Is NOVAVAX, INC.'s revenue growing?
Yes. Revenue grew 64.7% year on year, to $1.1B.
Does NOVAVAX, INC. pay a dividend?
No dividend is currently expected from NOVAVAX, INC., according to the latest market data.
What are the main risks for NOVAVAX, INC.?
Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Negative operating cash flow of $244.6M — the core business consumed more cash than it generated.
Answers are generated from the figures in this report (updated 8 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — NVAX
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade NVAX
Links open broker research pages. Not an endorsement or recommendation.
Research NOVAVAX, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.